Skip to main content

Advertisement

SpringerLink
Log in

Cardiac Complications of Chemotherapy: Role of Prevention

  • Cardio-oncology (S Francis, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

With recent novel therapies, cancer survival has improved and chemotherapy-induced cardiac toxicity including left ventricular dysfunction and heart failure has a greater potential impact on long-term outcomes. Hence, the prevention of cardiotoxicity should be an important objective when planning the therapy of cancer patients. Different pharmacologic and nonpharmacologic approaches have been shown to be effective in small trials, most of them in patients treated with anthracyclines. Treatment of cardiovascular risk factors, the implementation of a healthy lifestyle, and changes in the administration of anthracyclines have been shown to be effective to prevent cardiotoxicity, as is the administration of antioxidants such as dexrazoxane, and some cardiovascular drugs such as ACE-inhibitors and beta-blockers. Ongoing studies are analyzing the effects of these drugs on anthracycline- and trastuzumab-induced cardiotoxicity. Nevertheless, the future of the prevention of cardiac toxicity should include the study of the exact mechanism of toxicity of each cardiotoxic drug and the genetic individual susceptibility of each patient. With this information, correct risk stratification could be performed when planning the initial therapy and new drugs with less cardiotoxicity could be developed. Also, the diagnostic and prognostic value of different cardiac biomarkers and of imaging techniques for each cardiotoxic drug should be established. Finally, further large randomized studies are needed to confirm the results of prior pilot studies on the effects of cardioprotective drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102–11.

    Article  CAS  PubMed  Google Scholar 

  3. Eschenhagen T, Force T, Ewer MS, Keuenaer GW, Suter TM, Anker SD. CV side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1–10.

    Article  PubMed  Google Scholar 

  4. Lipshultz S, Lipsitz S, Sallen S, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.

    Article  CAS  PubMed  Google Scholar 

  5. Wouters K, Kremer L, Herman E, Lipshultz S. Protecting against anthracyclines-induce myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–78.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42. Study describing the molecular mechanism of anthracycline-induced cardiotoxicity. The results open the possibility to identify patients at high-risk of cardiotoxicity, and of developing less cardiotoxic drugs.

    Article  PubMed  Google Scholar 

  7. Khouri M, Douglas P, Mackey J, et al. Cancer therapy-induced cardiac toxicity in early breast cancer. Circulation. 2012;126:2749–63.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Zver S, Zadnik V, Bunc M, Rogel P, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007;85:408–14.

    Article  CAS  PubMed  Google Scholar 

  9. García-Alvarez A, García-Albéniz X, Esteve J, Rovira M, Bosch X. Cardiotoxicity of tyrosine-kinase-targeting drugs. Cardiovasc Hematol Agents Med Chem. 2010;8:11–21.

    Article  PubMed  Google Scholar 

  10. Curigliano G, Cardinale D, Suter T, et al. CV toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidlines. Ann Oncol. 2012;23 suppl 7:vii155–66. An actualized clinical guideline based on current evidence.

    Article  PubMed  Google Scholar 

  11. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of LV ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77–84.

    Article  PubMed  Google Scholar 

  12. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.1161/CIR.0b013e31829e8776.

    PubMed Central  Google Scholar 

  13. Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation. 2011;124:642–50. Good review on the beneficial effects of exercise on anthracycline-induced cardiotoxicity.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Chicco A, Hydock D, Schneider C, Hayward R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2006;100:519–27.

    Article  CAS  PubMed  Google Scholar 

  15. Smith L, Cornelius V, Plummer C, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Good systematic review on anthracycline cardiac toxicity showing that there is not sufficiently robust evidence to support clear evidence-based recommendations on different anthracycline treatment regimens or for routine use of cardiac protective agents or liposomal formulations, and that there is a need to improve cardiac monitoring in oncology trials.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Van Dalen E, Michiels E, Caron H, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;3, CD005006. Cochrane meta-analysis of all clinical trials comparing doxorubicin vs epirubicin, and conventional doxorubicin vs liposomal-encapsulated doxorubicin.

    PubMed  Google Scholar 

  17. Van Dalen E, Caron H, Dickinson H, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;6, CD003917. Cochrane meta-analysis of clinical trials performed until 2010 to prevent chemotherapy-induced cardiac toxicity. Only dexrazoxane is efficacious in preventing heart damage in patients treated with anthracyclines, and that there is no evidence of a lower response rate to cancer therapy. Negative effects on progression-free survival were not identified.

    PubMed  Google Scholar 

  18. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145–53.

    Article  CAS  PubMed  Google Scholar 

  19. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25:493–500.

    Article  CAS  PubMed  Google Scholar 

  21. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group. Leukemia. 2010;24:355–70.

    Article  CAS  PubMed  Google Scholar 

  22. Toko H, Oka T, Zou Y, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res. 2000;25:597–603.

    Article  Google Scholar 

  23. Vaynblat M, Shah HR, Bhaskaran D, Ramdev G, Davis WJ, Cunningham JN, et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583–6.

    Article  CAS  PubMed  Google Scholar 

  24. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001;414:71–8.

    Article  CAS  PubMed  Google Scholar 

  25. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820–8.

    Article  CAS  PubMed  Google Scholar 

  26. Cardinale D, Colombo A, Sandri M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–81. First study to prove the efficacy of a troponin-guided strategy of myocardial prevention with enalapril in patients in high-risk patients submitted to high-dose chemotherapy.

    Article  CAS  PubMed  Google Scholar 

  27. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker Valsartan on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisolone. Cancer. 2005;104:2492–8.

    Article  CAS  PubMed  Google Scholar 

  28. Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160:487e.1–7.

    Article  Google Scholar 

  29. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol. 2002;185:218–27.

    Article  CAS  PubMed  Google Scholar 

  30. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37:837–46.

    Article  CAS  PubMed  Google Scholar 

  31. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–62. Study demonstrating the cardioprotective effects of carvedilol on anthracycline-induced LV dysfunction.

    Article  CAS  PubMed  Google Scholar 

  32. El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE. Protective effect of carvedilol on adriamicyn-induced LV dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012;18:607–13.

    Article  CAS  PubMed  Google Scholar 

  33. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective parallel-group, randomized, controlled study with 36 month follow-up. Am J Hematol. 2010;85:894–907.

    Article  CAS  PubMed  Google Scholar 

  34. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced LV systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of LV dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61:2355–62. First study performed in patients with malignant hemopathies using enalapril and carvedilol at the time of hospital admission as a primordial prevention strategy, and showing a beneficial effect on chemotherapy-induced LV systolic dysfunction. Patients with acute leukemia treated with more intense chemotherapy regimens and including anthracyclines benefited the most from this prevention strategy.

    Article  CAS  PubMed  Google Scholar 

  35. Riad A, Bien S, Westermann D, et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res. 2009;69:695–9.

    Article  CAS  PubMed  Google Scholar 

  36. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60:2384–90.

    Article  CAS  PubMed  Google Scholar 

  37. Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988–9.

    Article  PubMed  Google Scholar 

  38. Blanco J, Leisenring W, Gonzalez-Covarrubias V, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H: quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789–95.

    Article  PubMed  Google Scholar 

  39. Visscher H, Ross CJD, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30:1422–8. One of the biggest genetic studies performed to find predictors of anthracycline-induced cardiotoxicity. 3000 single-nucleotide polymorphisms were evaluated in 156 patients, and the results replicated in two other cohort of patients.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Laura Carola Magnano, Dr. Nuria Martínez Cibrian, Dr. Xavier Andrade González , and Dr. Xavier Bosch each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Hematology Department, Hemato-Oncology Institute, Hospital Clinic, Barcelona, Spain

    Laura Carola Magnano MD, Nuria Martínez Cibrian MD & Xavier Andrade González MD

  2. Cardiology Department, Thorax Institute, Hospital Clinic, Villarroel 170, 08036, Barcelona, Spain

    Xavier Bosch MD, PhD

  3. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

    Xavier Bosch MD, PhD

Authors
  1. Laura Carola Magnano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nuria Martínez Cibrian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xavier Andrade González MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xavier Bosch MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Bosch MD, PhD.

Additional information

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Magnano, L.C., Martínez Cibrian, N., Andrade González, X. et al. Cardiac Complications of Chemotherapy: Role of Prevention. Curr Treat Options Cardio Med 16, 312 (2014). https://doi.org/10.1007/s11936-014-0312-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-014-0312-7

Keywords

Search

Navigation